Back to Search Start Over

Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth

Authors :
Willis, Jordan R.
Sapparapu, Gopal
Murrell, Sasha
Julien, Jean-Philippe
Singh, Vidisha
King, Hannah G.
Xia, Yan
Pickens, Jennifer A.
LaBranche, Celia C.
Slaughter, James C.
Montefiori, David C.
Wilson, Ian A.
Meiler, Jens
Crowe, James E., Jr.
Source :
Journal of Clinical Investigation. July, 2015, Vol. 125 Issue 7, p2523, 9 p.
Publication Year :
2015

Abstract

Several HIV envelope-targeting (Env-targeting) antibodies with broad and potent neutralizing activity have been Identified and shown to have unusual features. Of these, the PG9 antibody has a long heavy chain complementarity determining region 3 (HCDR3) and possesses unique structural elements that interact with protein and glycan features of the HIV Env glycoprotein. Here, we used the Rosetta software suite to design variants of the PG9 antibody HCDR3 loop with the goal of identifying variants with increased potency and breadth of neutralization for diverse HIV strains. One variant, designated [PG9_N100.sub.F]Y, possessed increased potency and was able to neutralize a diverse set of PG9- resistant HIV strains, including those lacking the Env N160 glycan, which is critical for PG9 binding. An atomic resolution structure of the [PG9_N100.sub.F]Y fragment antigen binding (Fab) confirmed that the mutated residue retains the paratope surface when compared with WT PG9. Differential scanning calorimetry experiments revealed that the mutation caused a modest increase in thermodynamic stability of the Fab, a feature predicted by the computational model. Our findings suggest that thermodynamic stabilization of the long HCDR3 in its active conformation is responsible for the increased potency of [PG9_N100.sub.F]Y, and strategies aimed at stabilizing this region in other HIV antibodies could become an important approach to in silico optimization of antibodies.<br />Introduction Recent studies have described the isolation of a number of human mAbs directed to the HIV envelope (Env) that exhibit broad and potent neutralizing activity, many of which exhibit [...]

Details

Language :
English
ISSN :
00219738
Volume :
125
Issue :
7
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.421907193
Full Text :
https://doi.org/10.1172/JCI80693